PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
40628732,Glioblastoma at the crossroads: current understanding and future therapeutic horizons.,2025 Jul 9,Singh S; Dey D; Barik D; Mohapatra I; Kim S; Sharma M; Prasad S; Wang P; Singh A; Singh G,"MLM Medical Labs LLC, Oakdale, MN, USA.",
40628625,"Expression of Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) on Malignant but Not Normal Plasma Cells Offers Novel Therapeutic Targets for Patients With Myeloma, Amyloidosis and Other Plasma Cell Dyscrasias.",2025 Jun 5,Sartor M; Lemarchand TX; Britz L; Er J; Harrison SJ; Dunn R; Gottlieb DJ,"Haemalogix Ltd, Sydney, New South Wales 2001, Australia.",
40627846,EML4-ALK rearrangement creates a distinctive myeloid cell-dominant immunosuppressive microenvironment in lung cancer.,2025 Jul 8,Arai K; Nishito Y; Mizuno H; Motoi N; Hiraoka N; Fuse M; Arai Y; Shibata T; Sonobe Y; Kayukawa Y; Maruyama T; Fukuda H; Mizoguchi Y; Aikawa Y; Yoshida Y; Watanabe SI; Sakamoto H; Yamashita M; Kitano S; Nagata Y; Mitsumori R; Ozaki K; Niida S; Kanai Y; Hirayama A; Soga T; Yoshida T; Yasuda K; Ochiai A; Tsunoda H; Aoki K,"Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan.; Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan.; Chugai Pharmaceutical Co., Ltd., Yokohama City, Japan.; Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan.; Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.",
40627813,RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).,2025 Jul 8,Wong MK; Milhem MM; Sacco JJ; Michels J; In GK; Couselo EM; Schadendorf D; Beasley GM; Niu J; Chmielowski B; Wise-Draper TM; Bowles TL; Tsai KK; Lebbe C; Gaudy-Marqueste C; Middleton MR; Skolariki A; Samson A; Chesney JA; VanderWalde AM; Zakharia Y; Harrington KJ; Appleton E; Bommareddy PK; Zhu J; Viana M; Hou JW; Coffin RS; Robert C,"Replimune, Inc., Woburn, MA, USA.; Replimune, Inc., Woburn, MA, USA.; Replimune, Inc., Woburn, MA, USA.; Replimune, Inc., Woburn, MA, USA.; Replimune, Inc., Woburn, MA, USA.",
40627448,NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING.,2025 Jul 8,Kim YS; Nabet BY; Cortez BN; Sun NY; Sebastian R; Redon CE; Ray A; Liu L; Ishola AA; Loew S; Dhall A; Sindiri S; Gayevskiy V; Lee MJ; Rastogi S; Sato N; Kedei N; Andresson T; Das S; Kumar S; Bers AE; Zhang H; Chiappori A; Gopal P; Abazeed ME; Chen H; Aladjem MI; Pommier Y; Velez MJ; Shames DS; Roper N,"Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.; Genentech Inc., South San Francisco, United States of America.; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.; Genentech Inc., South San Francisco, United States of America.; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.; Genentech Inc., South San Francisco, United States of America.; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.",
40624367,"EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma.",2025 Jul 7,Dimopoulos MA; Terpos E; Boccadoro M; Moreau P; Mateos MV; Zweegman S; Cook G; Engelhardt M; Delforge M; Hajek R; Schjesvold F; Gay F; Manier S; Weisel KC; Kaiser M; van de Donk NWCJ; Zamagni E; Rodriguez-Otero P; Perrot A; Driessen C; Bila J; Laane E; Dytfeld D; Touzeau C; Beksac M; Raab MS; Cavo M; Mohty M; Spencer A; Ludwig H; Einsele H; San-Miguel J; Sonneveld P,"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. eterpos@med.uoa.gr.",eterpos@med.uoa.gr
40623718,"Authors response to ""Letter to the Editor"": ""Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types"".",2025 Jul 7,Graf RP; Gandara DR,"Foundation Medicine Inc, San Diego, California, USA rgraf@foundationmedicine.com.",rgraf@foundationmedicine.com
40622253,Novel Autologous Regulatory T-Cell Therapy Ameliorates DSS-Induced Colitis in Humanized Mice.,2025 Jul 7,Khan MJ; Lee YJ; Lee SY; Chung H; Nguyen-Phuong T; Kim YH; Park CG; Kang YM,"Preclina Inc., 719 & 1302, Teratower B, 167, Songpa-daero, Songpa-gu, Seoul, South Korea.; Preclina Inc., 719 & 1302, Teratower B, 167, Songpa-daero, Songpa-gu, Seoul, South Korea.; Preclina Inc., 719 & 1302, Teratower B, 167, Songpa-daero, Songpa-gu, Seoul, South Korea.; Department of Basic Research, PB Immune Therapeutics Inc, Seoul, South Korea.; Department of Basic Research, PB Immune Therapeutics Inc, Seoul, South Korea.; Preclina Inc., 719 & 1302, Teratower B, 167, Songpa-daero, Songpa-gu, Seoul, South Korea.",
